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Abstract: Nonalcoholic fatty liver disease (NAFLD) defines a wide pathological spectrum ranging
from simple steatosis to nonalcoholic steatohepatitis (NASH) which may predispose to liver cirrhosis
and hepatocellular carcinoma. It represents the leading cause of hepatic damage worldwide.
Diagnosis of NASH still requires liver biopsy but due to the high prevalence of NAFLD,
this procedure, which is invasive, is not practicable for mass screening. Thus, it is crucial to
non-invasively identify NAFLD patients at higher risk of progression to NASH and fibrosis. It has
been demonstrated that hepatic fat content and progressive liver damage have a strong heritable
component. Therefore, genetic variants associated with NAFLD have been proposed as non-invasive
markers to be used in clinical practice. However, genetic variability is not completely explained
by these common variants and it is possible that many of the phenotypic differences result from
gene-environment interactions. Indeed, NAFLD development and progression is also modulated
by epigenetic factors, in particular microRNAs (miRNAs), which control at post-transcriptional
level many complementary target mRNAs and whose dysregulation has been shown to have high
prognostic and predictive value in NAFLD. The premise of the current review is to discuss the role of
miRNAs as pathogenic factors, risk predictors and therapeutic targets in NAFLD.
Keywords: non-alcoholic liver disease; NASH; fibrosis; HCC; PNPLA3; TM6SF2; MBOAT7; microRNAs;
epigenetics; intestinal permeability
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis, defined by fat
accumulation exceeding 5% of liver weight in the absence of alcohol abuse, to the progressive form
namely nonalcoholic steatohepatitis (NASH), which is characterized by lobular inflammation and
hepatocellular ballooning, and to hepatic fibrosis [1]. NASH may progress to cirrhosis and, in a small
percentage of patients, to hepatocellular carcinoma (HCC) [2,3]. NAFLD is becoming a leading cause
of liver damage worldwide, affecting between 20% to 40% of the adult population [4].
Pathogenesis of NAFLD is closely intertwined with excessive adiposity, insulin resistance
(IR) and dyslipidemia [5]. Dietary factors such as excessive caloric intake, fructose and physical
inactivity represent other risk factors for this condition [6]. Moreover, NAFLD has a strong
genetic component, and variants in proteins regulating hepatocellular lipid handling, including
Patatin-like Phospholipase Domain-containing 3 (PNPLA3), Transmembrane 6 Superfamily Member 2
(TM6SF2), Membrane Bound O-acyltransferase Domain-containing 7 (MBOAT7), predispose to the
development and progression to NASH and fibrosis [7]. However, less than 10% of genetic variability
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is explained by these common variants and it is possible that many of the phenotypic differences
result from gene-environment interactions, thus explaining the impossibility, till now, to define
NAFLD heterogeneity at genomic level [8]. Epigenetics, a hereditable but reversible phenomenon
that affects gene expression without modifying DNA sequence, provides a new perspective on
NAFLD pathogenesis and management [9]. The epigenetic modulation of gene expression may
occur in response to environmental cues as (1) modification of DNA nucleotides (e.g., methylation);
(2) modifications of histones that determine DNA packing and accessibility; and (3) regulation of
transcription by altering mRNA stability and activity due to specific binding of small RNA molecules
such as microRNAs (miRNAs).
Epigenetic modifiers in NAFLD can represent novel molecular indicators which can determine
not only the early risk assessment but also the disease progression and prognosis. Indeed, to date it
is not possible to predict NAFLD outcome through the routinely used blood and tissue biomarkers
due to their limited prognostic efficacy, tissue specificity and sensitivity. Liver biopsy remains the
gold standard procedure for diagnosis of NASH. However, it is invasive, potentially dangerous and is
generally performed when disease has progressed to clinically significant stages. Furthermore, due to
the high prevalence of NAFLD, liver biopsy is not practical for mass screening, not being feasible in the
30% of the population affected by NAFLD, including children and elderly patients, and for follow-up
and treatment monitoring. In this context, there is a growing need to identify novel and trustworthy
biomarkers, attempting to distinguish NASH from simple steatosis and to define severity of fibrosis.
Thus, circulating miRNAs have become appealing candidate molecules for diagnosis and staging of
liver diseases.
miRNAs control at post-transcriptional level many complementary mRNA targets and their
dysregulation has been shown to have high prognostic and predictive value in a broad spectrum
of rodents and human pathological liver conditions, including NAFLD [10]. Moreover, miRNAs
expression in human diseases appears to be tissue-specific. This would allow to identify miRNAs
secreted from the liver and to correlate them with the severity of the disease. In addition, miRNAs
possess high stability in formalin-fixed tissues and even in stored plasma samples, allowing their
use also in retrospective studies. Finally, circulating miRNAs have a key role as signaling molecules
because they are involved in cell-to-cell communication, as it occurs between hepatocytes and hepatic
stellate cells (HSCs) whose cross-talk may result in fibrogenesis and liver damage progression.
The role of miRNAs as pathogenic factors and their use as diagnostic/prognostic biomarkers in
NAFLD is the subject of this review, shedding light on the potential of miRNAs for the design of novel
therapeutic drugs.
2. miRNAs
MicroRNAs (miRNAs) are short non-protein coding, single-strands RNAs of 19–22 nucleotides,
that have a pivotal role in the regulation of gene expression [11]. miRNAs can target mRNAs
through complementary base-pairing, thereby leading to the post-transcriptional repression of targeted
protein-coding genes [11–13]. To date, there are more than 2000 known miRNAs encoded in various
intergenic, intronic or exonic sequences and it is estimated that miRNAs may directly target up to 60%
of all human genes [14]. Firstly transcribed as primary miRNAs (pri-miRNAs), these molecules are
further processed in two steps, within the nucleus and then in the cytoplasm, to form mature miRNAs
which exert either the silencing of target mRNAs or the repression of protein synthesis [11]. The targets
of miRNAs can be multiple genes (multi-functionality) or multiple miRNAs can target single gene
(redundancy) [15] suggesting that miRNAs have an extensive regulatory capacity and a profound
impact on health and disease [11]. Inherited variations that affect miRNAs-mRNA complementarity
may influence the repressive role of miRNAs, providing a possible explanation for individual variability
of transcriptome, through genetic and epigenetic interactions [16]. In addition, miRNA-coding genes
are exposed to regulatory mechanisms including DNA methylation and RNA editing, similarly to
protein-coding genes, leading to alteration in miRNA stability and to their degradation [15].
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miRNAs have been revealed in serum, plasma, saliva and urine and their association with
proteins, lipids and lipoproteins make them more stable in the circulation. Usually miRNAs are found
in complex with proteins, mainly Argonaute-2 (AGO2) [17] or packaged in extracellular vesicles,
mostly exosomes [18] where they are protected from RNase degradation. The release of circulating
miRNAs can occur via passive process during cell death or via active release of microvesicles from
cells [19]. For example, it has been demonstrated that the liver-specific miR-122 is found mostly
in the exosome-rich fraction in alcoholic and nonalcoholic liver injury, while it is predominant
in the protein-rich fraction in acetaminophen-induced toxic liver injury [20]. This suggests that
the distribution of miRNAs in the different compartments, protein versus vesicles, could provide
additional information regarding the pathogenesis and the identification of a specific miRNA pattern
as biomarkers of liver diseases.
Exosomal miRNAs
Exosomes are small vesicles (30–90 nm) which are released from many cellular types into the
extracellular space. Exosomes are considered the newest family member of “bioactive vesicles”.
They reflect their tissue or cell of origin by the presence of specific surface proteins and play a key
role in cell-to-cell communications (neighboring or distant cells), thus influencing the phenotype
of recipient cells. As above mentioned, some miRNAs preferentially are packaged and released in
exosomes (exomiRs) [21,22], suggesting that parent cells have mechanism to transfer these miRNAs
into exosomes. Moreover, exosomal miRNA expression is altered under pathological conditions [23].
In addition, with the discovery that exosomal miRNAs can function as ligand of Toll-like receptors
(TLRs) thus activating immune cells, a new interest in exosome study has been opened up [24].
Diverse methods are used for exosome isolation and this surely represents a limitation for their
use since different purification strategies may affect exosomal miRNA content [25]. Furthermore,
the large number of exomiRs may regulate different signaling pathways thus producing addictive
effects in recipient cells. Finally, it is difficult to measure the concentration of miRNAs carried by an
exosome. It is worth adding that the combination of exosomes with RNA interfere technology (RNAi)
is a promising method for gene therapy [26].
3. miRNA Signature in NAFLD
miRNAs may regulate a wide spectrum of biological processes and metabolic homeostasis,
including lipid synthesis, fatty acids and glucose catabolism, inflammation, proliferation, apoptosis
and necrosis, which have been known to be epigenetically deregulated in NAFLD [27]. Therefore,
alteration of miRNA expression in response to genetic/epigenetic factors or environmental conditions
may contribute to steatosis onset and NAFLD progression [28]. The enhanced cell death, that typically
occurs in NASH during ballooning degeneration, determines the release of several miRNAs into the
circulation. Therefore, circulating miRNAs have a role of physiological significance in the biology of
NAFLD and they mirror the histological features and the molecular events occurring in NAFLD [29].
Thus, they could be exploited as attractive candidate biomarkers for an accurate profiling of the
different stages of the liver injury, enabling the early diagnosis and the clinical monitoring of the
disease progression. Altered hepatic miRNA profile has been described in NAFLD and NASH both in
humans and in experimental models [10,30–32]. Several differentially expressed miRNAs have been
reported in plasma samples of NAFLD patients. Pirola et al. explored the circulating miRNA signature
associated with NAFLD revealing that, among 84 miRNAs analyzed, miR-122, miR-192, miR-19a/b,
miR-125b and miR-375 were up-regulated in simple steatosis and, in particular, miR-122, miR-192 and
miR-375 were even more dramatically enhanced in NASH [29], potentially distinguishing NASH from
simple steatosis.
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3.1. miR-122
miR-122 is the most abundant miRNA in human liver [33], representing more than 70% of the
total liver miRNA pool. During hepatocytes maturation, miR-122 stimulates the expression of 24
hepatocytes-specific genes, including hepatocyte nuclear factor 6 (HNF6) [34] and in liver regeneration
it has been reported to regulate hepatocytes proliferation and differentiation, recapitulating the
developmental processes [35]. It also interacts with numerous target genes involved in lipid and
cholesterol metabolism [36].
Serum miR-122 correlates with alanine aminotransferase (ALT) levels and liver fibrosis in NAFLD
patients. It also performs slightly better in the diagnosis of NAFLD severity than classical liver
disease markers, including aspartate aminotransferase (AST), ALT and plasma caspase generated
cytokeratin-18 (CK18) fragments [37]. Moreover, serum miR-122 was also positively correlated with
serum concentrations of CK18 [29] which has been proposed as a marker of NASH and disease severity.
Several studies provided evidence that chronic liver diseases derived from of different etiologies
are frequently correlated with increased miR-122 release in the circulation, thus representing a marker
of liver damage in general. However, Pirola et al. revealed that serum miR-122 was up-regulated
7.2-fold in NASH patients compared to healthy subjects and 3.1-fold compared to simple steatosis,
proposing it as an extra-hepatic fingerprint of NASH and as a hallmark of ballooning [29]. Thus,
a modulation of miR-122 expression may recapitulate many of the changes observed in the natural
history of NAFLD. However, an inverse correlation between hepatic and serum miR-122 levels has
been detected [10]. It has been shown that miR-122 was 10-fold down-regulated in the liver of NASH
patients compared to simple steatosis and was preferentially expressed at the edge of fatty-laden
hepatocytes, suggesting that the lower expression of miR-122 in liver could be a consequence of a
dynamic regulation of the rate of miRNA release into the circulation. In addition, the increased levels
of serum miR-122 were positively correlated with the severity of NAFLD in murine models, even in
absence of ALT elevation [38,39]. On the contrary, mice deficient for miR-122 rapidly developed NASH
due to heightened lipogenesis, impaired lipid secretion, up-regulation of Interleukin 6 (IL-6), Tumor
necrosis factor-alpha (TNF-α), C-C Motif Chemokine Ligand 2 (CCL2) and the recruitment of immune
cells. Reduction of miR-122 is also involved in the up-regulation of fibrotic pathways by inducing
Hypoxia-Inducible Factor 1-α (HIF1α) and Mitogen-Activated Protein Kinase 1 (MAPK1) and in HCC
development. These data suggest that miR-122 has a role in NAFLD progression [40,41]. miR-122
deleted mice displayed also lower serum triglyceride (TG) and cholesterol levels and exhibited hepatic
lipids accumulation. Consistently, mice treated with antagomirs which are nucleotides directed against
miR-122, displayed 30% decrease of plasma cholesterol and enhanced β-oxidation [42]. miR-122
silencing induced the up-regulation of genes involved in lipids catabolism and favored lipogenesis
in cellular models [10]. Opposite results were obtained after miR-122 over-expression [43] pointing
out miR-122 as a promising therapeutic target in the treatment of hypercholesterolemia and other
dyslipidemias [44].
Enhanced circulating levels of miR-122 have also been detected in patients with other liver
diseases, such as viral hepatitis B and C (HBV, HCV) as well as in alcohol-and drug-induced liver
injuries [45–48]. As in alcoholic and nonalcoholic liver injury, hepatic miR-122 was down-regulated
also in patients with chronic HBV infection and inversely correlated with hepatic necroinflammation
and viral load. By targeting cyclin G1, miR-122 prevents cyclin G1-p53 interaction thus hampering
p53-mediated inhibition of HBV replication [49]. Conversely, miR-122 expression is paradoxically
increased during HCV infection to prompt viral replication [50], possibly discerning these two viral
infections [51]. Also, alcohol consumption has been proven to be involved in HCV replication. Indeed,
ethanol-induced higher levels of miR-122 which, in turn, targets several disease modifiers in HCV
infection further contributing to viral replication [52,53].
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3.2. miR-192
miR-192 is a pro-fibrogenic molecule induced by transforming growth factor β 1 (TGFβ1), that is
involved in fibrosis development and in the activation of TGFβ/SMAD signaling. miR-192 was found
to be mainly expressed in quiescent HSCs, favoring the inhibition of HSCs activation, proliferation
and migration [54].
As previously described for miR-122, also miR-192 was increased in NASH serum compared
with steatosis and down-regulated in NASH liver, both in human and animal models suggesting that
these miRNAs are released from hepatocytes during pathophysiological states associated with cell
membrane impairment [37] and they could be proposed a possible NASH biomarkers.
3.3. miR-375
miR-375 is considered to be a key regulator of glucose homeostasis and it is essential for β-cells
expansion in response to increasing insulin demand in insulin resistant conditions. It has been found
significantly up-regulated in NASH patients compared to simple steatosis [29]. It has been recently
described that miR-375 expression was increased in serum of mice fed high fat diet (HFD) compared to
healthy controls. Moreover, inhibition of miR-375 up-regulated the expression of adiponectin, inhibited
lipid accumulation and down-regulated both the level of leptin and inflammatory cytokines including
TNF-α and IL-6 in human hepatocellular carcinoma cells (HepG2) treated with fatty acids. In addition,
it has been demonstrated that adiponectin receptor 2 (AdipoR2) was a target of miR-375 which directly
binds to its 3’UTR. These findings highlighted the potential use of miR-375 as a novel therapeutic
target in NAFLD [55]. miR-375 seems to be involved also in HCC. Previous studies have shown
that miR-375 mimic inhibits autophagy in HCC through targeting the Autophagy-related gene 7
(ATG7) [56]. In addition, miR-375 suppresses malignant phenotypes of HCC by targeting Astrocyte
elevated gene-1 (AEG-1) and Yes-associated protein 1 (YAP1) which mediate steatosis and hepatic
proliferation/differentiation respectively [57,58].
4. miRNA Signature in Progressive NAFLD
In addition to the aforementioned miRNAs, which better discriminate simple steatosis from
NASH, several other miRNAs have been identified to exert a central role in the development of
steatosis and its progression to NASH, fibrosis and HCC. Cermelli et al. revealed the presence of
increased serum concentrations of miR-122, miR-34a and miR-16 in NAFLD patients compared to
healthy controls and a correlation of their expression with liver enzymes, inflammation and fibrosis
stage, suggesting that they may represent novel non-invasive biomarkers of progression from steatosis
to NASH [45]. Yamada et al. found enhanced serum abundance of miR-122, miR-21, miR-34a and
miR-451 in a cohort of NAFLD-diagnosed patients compared to controls, paralleling the steatosis
grade [39]. Tan et al. proposed miR-1290, miR-27b-3p and miR-192-5p as a panel of high diagnostic
accuracy for NAFLD, regardless the NAFLD activity score (NAS). This panel has a significant clinical
value in NAFLD diagnosis, since it is more sensitive and specific than ALT and Fibrosis 4 (FIB-4)
score [59]. Guo et al. reported that NAFLD severity is associated with a specific pattern of altered
hepatic miRNA expression that may drive the hallmark of this disorder, altered lipid and carbohydrate
metabolism. Specifically, the authors indicated miR-301a-3p, miR-34a-5p and miR-375 as potential
markers of NAFLD severity [60]. Over the past years, evidence has emerged that miRNAs which
are involved in the regulation of hepatic cholesterol and lipid metabolism (i.e., miR-122, miR-33a/b,
miR-29 and others) may further mediate the development of metabolic disturbance, atherosclerosis
and cardiovascular disease, confirming NAFLD as a systemic disorder [61]. More recently, Blaya et
al. revealed that miR-155 expression is altered in both liver tissue and circulating inflammatory cells
during liver injury, regulating inflammatory cells recruitment and liver damage. Thus, modulation
of miR-155 has been proposed to be a potential strategy to damp liver injury [62]. Finally, Zhu et al.
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identified 17 miRNAs, among which miR-144-3p, miR-99a-3p, miR-200b-3p, miR-200b-5p, as novel
potential biomarkers of NAFLD [63].
4.1. miR-33a and miR-33b
miR-33a and miR33b are co-transcribed with the Sterol regulatory element-binding protein
1 (SREBP1) and SREBP2 [64], key regulators of de novo lipogenesis and cholesterol biosynthesis,
localizing in the intronic regions of SREBP genes. miR-33a and miR-33b are positive regulators of these
two transcription factors and both target the α-subunit of the AMP-activated protein kinase (AMPK),
inhibiting its expression [65,66]. Moreover, they also play a key role in post-transcriptional repression
of ATP-binding cassette transporter sub-family A member 1 (ABCA1), which is essential for cholesterol
binding to Apolipoprotein A1 (APOA1) during high density lipoprotein (HDL) formation [67]. For this
reason, they contribute to the modulation of fatty acids metabolism, cholesterol synthesis and insulin
signaling pathways. Therefore, the inhibition of these miRNAs enhanced insulin sensitivity, fatty acids
oxidation and circulating levels of HDL as well as reduced lipid accumulation in arterial plaques,
raising the possibility to use them as therapeutic targets in the management of metabolic syndrome,
atherosclerosis and NAFLD [68]. Likewise, miR-33a was highly expressed in activated HSCs due to
the modulation of phosphatidylinositol-3-kinase/protein kinase B (PI3k/PKB) pathway and correlated
with TGFβ-induced expression of type I collagen (Col1A1) and α-smooth muscle actin (αSMA),
suggesting its involvement in fibrosis development [69,70].
4.2. miR-34a
miR-34a is highly expressed in patients with type 2 diabetes mellitus (T2DM), steatosis, NASH
and in experimental models of NAFLD [71,72]. It was positively correlated with very low-density
lipoprotein (VLDL), TG and serum ALT. miR-34a is the most characterized regulator of Sirtuin 1
(SIRT1), a NAD-dependent deacetylase [45]. miR-34a is a highly lipid responsive miRNA in the liver,
modulating oxidative stress and metabolism, and it has been reported that it regulates apoptosis,
DNA damage and telomere attrition in cardiac senescence and ischemic diseases [73]. Silencing of
miR-34a restored the expression of SIRT1 and Peroxisome proliferator-activated receptor α (PPARα),
resulting in activation of PPARα downstream genes, such as AMPK and Hydroxymethylglutaryl-CoA
Reductase (HMGCR), thus ameliorating steatosis [74]. Conversely, induction of miR-34a is related to
Hepatocyte nuclear factor 4α (HNF4α) inhibition in NAFLD patients, inflammation through Nuclear
Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) activation and hepatocellular
apoptosis [72]. Xu et al. demonstrated that miR-34a inhibited VLDL secretion from the liver, promoting
steatosis onset through the interaction with HNF4α in NASH patients and in HFD-fed mice [75].
In addition, the over-expression of miR-34a in vitro exacerbated free fatty acids (FFA)-induced
oxidative stress and apoptosis [76]. Notably, miR-34a has been also recognized to act on the repression
of β-Klotho, a co-receptor of the Fibroblast growth factor 19 (FGF19), implicated in glucose metabolism
during post-prandial response in physiological states. Indeed, inhibition of miR-34a in ob/ob mice
ameliorates obesity and restores β-Klotho/FGF19 signaling [28,77].
4.3. miR-451
Hepatic lipid accumulation and inflammation usually occur together. There is a growing evidence
supporting the role of innate immunity in NASH. In particular, TLR signaling induces the expression
of a variety of miRNAs, as well as several miRNAs can modulate TLRs [78]. miR-451 is responsive
to fatty acids and a reduced hepatic expression of miR-451 is detected in human NASH, in HepG2
cells treated with palmitic acids and in mice fed HFD [79]. miR-451 could regulate dendritic cell
cytokines and suppress chemotaxis. Down-regulation of miR-451 led to increased activation of
NF-κB and to enhanced secretion of IL-8 and TNF-α [79]. Conversely, the over-expression of miR-451
decreased inflammatory cytokines release [79]. These evidences highlight new insights into the negative
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regulation of miR-451 in fatty acid-induced inflammation, pointing out its potential therapeutic
applications [15].
4.4. miR-155
One of the miRNAs that could regulate Kupffer cells (KCs) is miR-155. It is involved in
inflammatory processes that control innate and adaptive immunity in both alcoholic and nonalcoholic
fatty liver disease [80,81]. It was found highly expressed in hepatocytes and in KCs, isolated from
mice fed Methionine Choline-deficient diet (MCD), where it contributes to Lipopolysaccharides (LPS)
sensitization and TNF-α production [80,81]. In particular, miR-155 was up-regulated in response to
LPS and enabled TNF-α mRNA stability and protein synthesis. By promoting the proinflammatory
process through TNF-α, miR-155 may be further favor atherosclerotic plaque rupture [82]. Conversely,
in isolated KCs the treatment with IL-10 or TGFβ suppressed miR-155 expression [83]. Consistently,
in RAW264.7 macrophages, the immunosuppression of KCs/macrophages could be positively
regulated by miR-155 inhibition. Indeed, in liver ischemia-reperfusion injury mice, miR-155 deficiency
resulted in the development of M2 macrophages and produced a regulatory inflammatory response
with higher levels of IL-10 and lower levels of TNF-α, IL-6 and IL-12p40 [84]. However, miR-155
knock-out mice failed to hamper liver inflammation although steatosis and fibrosis were reduced [81].
In fact, it plays also an important role in the initial hepatic lipid accumulation, targeting Liver X
receptor alpha (LXRα) and modulating lipid metabolism [81].
miR-122, miR-192, miR-155, miR-34a are detectable in liver diseases from different etiologies [27].
However, it has been observed that they are more up-regulated in patients with NASH, possibly
representing specific biomarkers for this pathological condition. To date, it is difficult to assign a
miRNA profile, which is specific for NASH and further studies are surely required.
5. Role of miRNAs in Adipose Tissue and Gut Homeostasis
The excessive expansion of visceral adipose tissue (VAT) results in chronic low-grade inflammation
and adipocytes along with macrophages secrete several mediators (referred to as adipokines), that are
essential in the complex cross-talk between liver and adipose tissue which occurs in patients with
metabolic syndrome [85]. Several adipokines have been reported to be related to changes in miRNA
profile and differential miRNAs expression was found not only in the liver, but also in VAT of NAFLD
patients [86]. In biopsy-proven NASH, the VAT expression of miR-7.1, miR-132, miR-150, miR-433,
miR-28-3p, miR-511, miR-517a, miR-671 is statistically different compared to healthy subjects [86].
Likewise, in NASH patients, VAT altered gene expression of miRNAs processing enzymes (Dicer1,
Drosha, DGCR8) was also reported. Thus, obesity results in a unique miRNA profile and different stages
of NAFLD are related to diverse miRNA signatures. Some of those differentially expressed miRNAs
correlate with body weight and metabolic parameters, affecting adipocytes differentiation, adipose
tissue inflammation and hypothalamic regulation of energy homeostasis. For example, miR-125b
levels were positively related to fasting glucose, TGs concentrations and to the body mass index (BMI)
both in serum and in VAT [29,87].
It has also been described that miRNA-containing adipose tissue macrophages (ATM)-exosomes
can modulate systemic insulin and glucose tolerance by directly affecting cellular insulin signaling.
miR-155 contributes to the insulin resistant, glucose intolerant state conferred by obese ATM-Exos by
repressing PPAR-γ, possibly in a coordinated way with other miRNAs. It could be speculated that
ATM-Exos miRNAs represent a paracrine and endocrine signaling system, whereby proinflammatory
and anti-inflammatory ATMs can influence metabolic events in distant tissues [88]. Chai et al. found
that FFAs increase hepatic expression and secretion of miR-122, which regulates energy storage versus
expenditure in liver and peripheral tissues. Strategies to reduce triglyceride levels, by increasing
miR-122, might be developed for treatment of metabolic syndrome [89].
Additionally, gut microbiome changes influence obesity and the pathogenesis of NAFLD/NASH.
Indeed, the liver is exposed to high concentration of gut-derived microbial components and a well
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characterized feature of NAFLD is represented by the increased intestinal permeability, resulting
in enhanced steatosis and inflammation, due to the high influx of TLRs ligands [90]. miRNAs may
modulate also the expression of genes involved in microbial recognition or vice versa they may be
induced by microbial products. Indeed, several studies demonstrated that germ-free mice colonized
with the microbiota from pathogen-free mice induced changes in host miRNAs, in response to
microbiota colonization, suggesting that the intestinal bacteria participate also in the modulation
of miRNAs, which could in turn regulate host gene expression. Mice carrying intestinal epithelial cell
(IEC)-specific Dicer deficiency displayed higher levels of miR-122 which induces a degradation of
occludins leading to an increased intestinal permeability [91]. Similarly, miR-375, miR-146a, miR-155,
miR-29 and miR-10a were implicated in the alteration of intestinal environment. Particularly both
miR-212 and miR-155 can down-regulate components of tight junctions including Zonula Occludens
1 (ZO-1) and up-regulate the levels of inducible Nitric oxide synthases (iNOS) resulting in intestinal
barrier dysfunction [27]. In particular, miR-212 is highly expressed in intestine and the ethanol exposure
could induce miR-212 expression in Caco2 cells. In HFD mice, the relative abundance of Firmicutes
was negatively correlated with hepatic expression of miR-666 and miR-21. In contrast, the relative
abundance of B. acidifaciens was positively correlated with miR-21 suggesting that gut microbiota may
govern hepatic pathophysiology during metabolic alterations [92]. Moreover, miR-21 knock out mice
displayed attenuated inflammation and tissue injury, improving the survival rate in dextran sulfate
sodium (DSS)-induced fatal colitis [93].
6. miRNAs in Liver Fibrosis and HCC
Hepatic fibrosis is the most frequent outcome of chronic liver disease, characterized by deposition
of extracellular matrix (ECM) and alteration of normal hepatic parenchyma. It has been described
that the stage of fibrosis may be the main cause of vascular events and non-hepatic cancer, to which
50% of deaths are attributable [94]. Approximatively 15–30% cases of NASH may progress to hepatic
fibrosis and encounter portal hypertension, cirrhosis development and eventually liver failure [95,96].
Furthermore, high percentage of patients with NASH develop HCC either in the presence or not of
cirrhosis, being HCC the fifth most prevalent cancer and the third leading cause of cancer-related
deaths worldwide [97].
The key event of hepatic fibrogenesis is represented by the activation of HSCs. They amount to
~8% of hepatic cell types, localized in the space of Disse and maintain a non-proliferative quiescent
state until stimulation. Chronic hepatic injury of any etiology and inflammatory signals (i.e., TGFβ)
could be the main cause of HSCs trans-differentiation into myofibroblast-like phenotype, also termed
activated state. Activated HSCs are the primary source of scar tissue deposition and are featured by
higher cell proliferation rate, loss of vitamin A-containing lipid droplets, induction of αSMA and drive
fibrosis mainly by secreting ECM proteins and fibrillar collagens [98]. Likewise, repeated cycles of
disruption and compensatory tissue regeneration due to sustained inflammation and hepatic damage
may lead to hepatic carcinogenesis [97].
As highlighted, the study of epigenetic mechanisms is achieving considerable relevance to
discover novel blood-based noninvasive biomarkers to monitor and manage NAFLD progression
whereby treatment is still available.
As previously mentioned, Cermelli et al. observed that miR-122, miR-34a and miR-16 circulating
levels were strongly correlated with liver enzymes, inflammation activity and fibrosis score [45].
Confirming these findings, in a retrospective study which considered 52 patients with fibrosis of
various etiologies, miR-122 was negatively correlated with fibrosis stage and liver stiffness values [99].
Conversely, Celikbilek et al. showed that miR-181d, miR-99a, miR-197 and miR-146b levels were
significantly reduced in sera of 20 histologically proven NAFLD compared to control group and
miR-197 and miR-10b negatively correlated with inflammation. However, this study did not reveal
changes in miR-122 and miR-34a serum expression in NASH patients and healthy controls [100].
Additionally, many other reports showed deregulated hepatic levels of miRNAs by comparing tumoral
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tissues to non-cancerous ones. Although analysis of miRNA signature in HCC samples embedded
by bioinformatic tools, revealed several miRNA candidates and their target genes involved in liver
tumorigenesis, these results do not always overlap, possibly due to different HCC etiologies, genetic
background, sex, age but also biases from technique protocols or differences in patients’ samples [101].
Despite the clinical relevance of liver fibrosis and cancer, the mechanisms underlying hepatic
fibrogenesis and carcinogenesis are still under definition thus constraining appropriate strategies for
prevention and pharmacological therapies. In this contest, identification of specific miRNA panel
related to liver disease severity seems to be a promising non-invasive approach for diagnosis, prognosis
and preventive interventions [68].
6.1. miR-15 and miR-16
miR-15 and miR-16, both members of miR-15 family, also including miR-497, miR-195 and
miR-322 [102], raised a great interest for their involvement in liver fibrosis and hepatocarcinogenesis.
Higher circulating levels of miR-16 were observed in individuals affected by NAFLD compared to
healthy controls and correlated with the severity of liver disease, supporting their use as biomarkers
for NAFLD staging [45]. miR-16 dysregulation may promote liver fibrosis in HSCs by up-regulating
guanine nucleotide-binding α-subunit 12 (Gα12), a key transductor of G-protein coupled receptors
(GPCRs) network signaling. Gα12 interaction with ATG12-5 is a pro-fibrogenic signal which stimulates
HSCs activation through autophagy-mediated breakthrough of lipid droplets [103,104].
In addition, Guo and coworkers revealed a set of 21 differential miRNA expression by comparing
rat quiescent HSCs to activated ones. Among them, examination of the seed region in miR-15/16
sequence showed complementarity of six nucleotides with anti-apoptotic B-cell lymphoma-2 (Bcl2)
factor at 3’UTR mRNA sequence [105]. Indeed, miR-15 and miR-16 down-regulated Bcl-2 at
post-transcriptional level and their expression is reduced during HSCs activation. Primary rat HSCs
derived by carbon tetrachloride (CCl4)-induced hepatic fibrosis model showed increasing Bcl-2 levels
and lower expression of caspase-9 compared to normal controls, supporting their pro-apoptotic role in
HSCs via targeting Bcl-2 and members of caspase signaling [105,106].
miR-15/16 are also involved in the regulation of cell cycle progression, proliferation and
oncogenesis [106]. miR-15/16 clusters are well-known tumor suppressor, by inhibiting numerous
oncogenes and their deregulation was also observed in multiple in vitro and in vivo models [107,108].
In MHCC97H, a high invasive subtype of HCC cell line, miR-15a expression was lower than in a less
tumorigenic hepatocytes cell line (Huh7), suggesting its levels might be associated to more aggressive
HCC phenotype [108]. In patients with HCC, miR-15a levels were reduced in cancerous hepatic
tissue and they negatively correlated with lymph nodes metastasis and TNM classification [109].
Besides miR-15a, aberrant expression of miR-16 is also implicated in cancer development. HepG2
over-expressing miR-16 exhibited less proliferative, invasive and metastatic phenotype and these effects
may be attributed to increased apoptotic-related proteins and diminished levels of metalloproteases.
In addition, transient transfection of HepG2 cells with miR-16 inhibitor showed growing levels of PI3K
and phosphorylated Akt, which are widely involved in numerous biology processes among which
proliferation, migration, invasion and ECM formation [110].
6.2. miR-34
Members of miR-34 family gained great attention for their pleiotropic functions in regulation
of proliferation, differentiation and programmed cell death. miR-34a is one of the most increased
miRNAs during hepatic fibrogenesis in both animal models and human patients with different
hepatopathies [10,111]. In rodents, miR-34a inhibits the acyl-CoA synthetase 1 long-chain family member
1(Acsl-1) enzymatic activity, which promotes lipid accumulation in hepatocytes and HSCs [112–114].
Silencing of miR-34a up-regulates Acsl-1 and decreases the expression of αSMA, Col1A1 and desmin
as well as prompts lipogenesis in HSCs by up-taking fatty acids and contributing to maintain
quiescent HSC phenotype [114]. In addition, the interaction of miR-34a and miR-34c with PPARγ,
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an anti-fibrotic factor, represents another mechanism of regulation of human HSCs activation [113].
In hepatocytes, miR-34a targets SIRT1 and caspase 2 (CASP2), which commonly increase apoptosis
susceptibility, also contribute to ECM remodeling via up-regulation of metalloproteinase 2 and 9
(MMP2, MMP9) [111,115].
miR-34a, apoptosis and acetylated-p53 increase with disease severity whereas SIRT1 expression is
reduced in NAFLD patients. Throughout hepatic injury, increased miR-34a levels promote apoptosis by
targeting SIRT1. Rats with CCl4-induced fibrosis showed reduced miR-34a levels and p53 acetylation
in hepatocytes but not in HSCs upon SIRT1 activator exposure. Such findings support a cell-specific
mechanism of action of miR-34 to promote hepatic fibrogenesis [111,115]. Ursodeoxycholic acid
(UDCA) is a potent inhibitor of p53-dependent pathways. The p53/miR-34a/SIRT1 pro-apoptotic
pathway is prevented by UDCA in primary rat hepatocytes even after miR-34a overexpression,
a condition that mimics increased miR-34a levels in patients with severe NAFLD [72]. A possible
explanation is that UDCA, by blocking p53 transactivation, inhibits mir-34a expression and on the
other hand it seems that modulation of SIRT1 by UDCA depends almost exclusively on miR-34a.
The inhibition of the p53/miR-34a/SIRT1 pathway prevented the miR-34a-mediated repression of
SIRT1 and lead to reduced p53 acetylation and apoptosis, thus representing a novel therapeutic target
for NAFLD progression.
miR-34a is also becoming highly studied in cancer although its role is still controversial [116,117].
miR-34a may affect hepatocytes proliferation and apoptosis. Hep3B and HepG2 cell lines over-expressing
miR-34a showed higher cell death rate, as proven by increased expression of anti-apoptotic proteins (i.e.,
Bcl2), and inversely correlation of Histone deacetylase 1 (HDAC1) expression, which is currently
considered as therapeutic target in malignancies. Comparison between cancerous and adjacent normal
hepatic tissues of 60 patients with HCC confirmed that miR-34a levels were lower whereas HDAC1
mRNA expression was markedly higher in tumor samples [118]. The anti-cancer effects of 0404,
a novel DNA-damaging compound, were investigated in several human HCC cell lines and HCC
xenograft mouse model. 0404 up-regulates miR-34a and increased p53 acetylation in both in vitro
and HepG2-bearing nude mice, suggesting that its anti-tumoral activity on HCC was exerted via
p53/miR-34a/SIRT1 pathway [119].
6.3. miR-21
miR-21 is one of the most up-regulated miRNAs in serum and hepatic tissues of individuals with
fibrosing-NASH and HCC [120,121]. Rodrigues et al., for the first time, reported that miR-21 knock-out
animals fed a fast food diet supplemented with obeticholic acid (OCA) displayed minimal steatosis,
inflammation and lipo-apoptosis through PPARα up-regulation and Farnesoid-X Activated Receptor
(FXR) activation [122]. In dietary obese mice and human HepG2 treated with fatty acids, miR-21
expression was increased. Furthermore, several studies pointed out a strong miR-21 up-regulation in
activated HSCs and this miRNA has been also proposed as biomarker for myocardial fibrosis [122–124].
miR-21 may modulate fibrogenesis by targeting phosphatase and tensin homolog (PTEN) thus favoring
Akt activation [123]. Additionally, ablation of miR-21 blocks epithelial-mesenchymal transition (EMT)
of hepatocytes and suppresses Extracellular signal-regulated kinase 1 (ERK1) during HSCs activation
through regulation of both HNF4α and MAPK inhibitor Sprouty 2 (SPRY2) expression [121]. Recently,
miR-21 has been proposed to play a role in steatosis progression towards HCC by inhibiting HMG-Box
Transcription Factor 1 (HBP1). HBP1 enhanced p53 activity which usually suppresses cell cycle-related
proteins and lipogenesis by blocking Central Communication Network (CCN) D1/B1 and SREPB1c,
respectively [125].
6.4. miR-221/222
miR-221 and its homologous miR-222 are a cluster of ~22 nucleotide which are encoded on the X
chromosome from a single transcript and differ for only 3 nucleotides downstream the seed region
influencing miRNA activity [126] . Although they were widely studied in the oncologic field, Ogawa
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et al. reported the first evidence that miR-221 and miR-222 were up-regulated in 26 patients affected by
NASH in a fibrosis-dependent manner and correlated with Col1A and αSMA expression in activated
primary mouse HSCs. Increased levels of miR-221/222 were also observed in mice with hepatic fibrosis
induced by thioacetamide (TAA) administration or MCD diet compared to controls [127].
As mentioned, miR-221/222 gained a great interest in cancer research. Pineau et al. find out
a panel of 12 miRNAs which may define progressive liver disease. According to the type of cancer
biology, miR-221/222 could function either as tumor suppressor or oncogene (oncomiRs). In the
liver, miR-221 seems to favor tumorigenesis by targeting tumor suppressor p27 or, alternatively,
DNA damage-inducible transcript 4 (DDIT4), an essential regulator of mTOR kinase activity [116].
Antimirs-based strategies revealed that miR-221 suppression prevented HepG2 cell growth, invasion
and induced apoptosis. Stable over-expression of antimir-221 in subcutaneously implanted HepG2 in
nude mice prevented tumor establishment and organ metastasis [128].
In addition, hepatic miR-221 over-expression was correlated with poor prognosis in patients
stratified for HCC staging [129].
miRNAs which are involved in progressive NAFLD in different cell type, representing possible
candidate biomarkers, are listed in Figure 1 and Table 1.
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Figure 1. Role of miRNAs in progressive NAFLD. Schematic illustration of candidate miRNAs
demonstrated to affect the progression of liver damage. In this figure, we reported the relative miRNA
expression in different hepatic cell types (hepatocytes, inflammatory cells i.e., Kupffer cells, HSCs) and
tissues (gut and VAT) influencing early and late stages of liver injury. Several miRNAs can be secreted
into the circulation triggering steatosis onset, inflammation and ECM deposition. Circulating miRNA
can be released via passive (i.e., cell death in apoptotic bodies) or active processes inside exosomes,
micro vesicles, HDL and AGO2 and can be easily detected in blood circulation as diagnostic, prognostic
and predictive biomarkers.
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Table 1. List of candidate miRNAs proposed as non-invasive biomarkers, predictors and therapeutic targets in nonalcoholic fatty liver disease (NAFLD).
Candidate Biomarkers Serum Liver Function Experimental Model NAFLD Severity Ref.
miR-122 Up-regulated Down-regulated
Lipid metabolism
Intestinal permeability modulation
Inflammation
Fibrogenesis
Proliferation
Human
MCD mice
In vitro
Steatosis NASH Fibrosis
HCC [29,38–40,71]
miR-192 Up-regulated Down-regulated HSCs activation Human
Steatosis
NASH
Fibrosis
[29,54]
miR-375 Up-regulated Up-regulated
Glucose homeostasis
Intestinal permeability modulation
Inflammation
Human
HFD mice
In vitro
Steatosis
NASH
HCC
[29,55,56]
miR-125b Up-regulated Up-regulated
Lipid and glucose homeostasis
Adipocytes differentiation
HSCs activation
Fibrogenesis
Human Steatosis NASH Fibrosis [29,87]
miR-33a/b Up-regulated Up-regulated
Lipid and cholesterol metabolism
Glucose homeostasis
HSCs activation
Human
Non-human primates
HFD mice
MCD mice
In vitro
Steatosis
NASH
Fibrosis
[66,69,70]
miR-34a Up-regulated Up-regulated
Lipid metabolism
Oxidative stress
Apoptosis
Proliferation
Human
HFD mice
In vitro
Steatosis NASH
Fibrosis
HCC
[71,72,75,76]
miR-451 Up-regulated Down-regulated Inflammation
Human
HFD mice
In vitro
NASH [39,79]
miR-155 Up-regulated Up-regulated
Lipid metabolism
Intestinal permeability modulation
Inflammation
Human
MCD mice
In vitro
NASH [81]
miR-221/222 Up-regulated Up-regulated
HSCs activation
Fibrogenesis
Sorafenib resistance
Human
TAA mice
MCD mice
In vitro
NASH
Fibrosis
HCC
[116,127,137]
miR-15/16 Up-regulated Down-regulated HSCs activationProliferation and Metastasis
Human
CCl4 rats
In vitro
Fibrosis
HCC [45,108,109]
miR-21 Up-regulated Up-regulated
Gut microbiota modulation
Inflammation
EMT
Proliferation
Human
HFD mice
In vitro
NASH Fibrosis
HCC [92,93,122,125]
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7. miRNA Hereditability in NAFLD
The major epidemiological modifiers in the epidemiology of NAFLD are obesity, T2DM and
dyslipidemia [130]. Sedentary lifestyle and high caloric diet consumption are the main environmental
factors that contribute to NAFLD. Nevertheless, NAFLD has also a strong heritable component [131,132].
Previous studies have been demonstrated that serum biomarkers (e.g., γ glutamyl transferase, GGT)
are hereditable [133]. Hereditability of epigenetic factors is not completely understood. Recent
studies in mammals have provided evidence that exposure to environmental stressors can drive
stably inherited phenotypic adaptations in offspring that are inherited by epigenetic, rather than
genetic mechanisms and some of these studies concern the development of liver disease. Indeed,
male inbred mice fed a low protein diet had offspring that increased liver expression of genes involved
in lipid and cholesterol metabolism [134]. Previous studies of DNA methylation in monozygotic twins
showed a great hereditability with similar epigenetic profiles between twins [135] although the main
differences in epigenetic variability were observed in twins who differed in lifestyle and age. Recently,
Zarrinpar et al. by using a twin-study design, demonstrated that serum miRNAs explain discordancy
between twins with and without NAFLD. In particular, miR-331-3p and miR-30c not only explained
NAFLD discordancy between twins but also were significantly different between participants with
and without NAFLD. Participants of this study although genetically similar lived separately as adults
and environment was not a confounding factor. miR-122 which has been associated with NAFLD,
seems not to be hereditable. It could be speculated that miR-122 could be the result of environmental
perturbations, and hence, not linked to host genetics, whereas miR-331-3p and miR-30c could be more
affected by genetic processes [136].
8. Epigenetic Therapies Which Target miRNAs
A translational epigenetic therapy in liver disease is represented by the miR-122 antagonist
miravirsen (SPC3649), a locked nucleic acid-modified DNA phosphonothioate antisense oligonucleotide
that sequesters miR-122 in a stable heteroduplex, inhibiting its function. Preclinical studies showed
that miR-122 is essential for stability and propagation of HCV RNA [138]. Miravirsen was the first
parenterally administered miRNA drug developed against HCV with a potential impact on NAFLD
since many genes regulated by miR-122 are involved in lipid metabolism. Studies in chimpanzees
showed a marked suppression of plasma and liver HCV RNA in animals that received the highest dose
of miravirsen [139] whereas dose-dependent reductions in HCV RNA levels were observed after 5
weekly administrations of miraversen in non-cirrhotic patients infected with HCV genotype 1 without
evidence of viral resistance [140]. However, other miR-122 targets could be affected by miravirsen as
demonstrated by phase IIa study results which revealed that antagonism lowered serum cholesterol
levels. In general, therapeutic approaches based on miRNA targeting may be problematic due to their
high redundancy and multi-functionality. Further studies will be necessary to explore the applicability
of miRNA modulators in the therapy of NAFLD.
Although there are no approved studies for the therapeutic use of miRNAs in HCC, MRX34,
a liposome-formulated miR-34 mimic developed by Mirna Therapeutics (Austin, TX, USA), produced
complete HCC regression in mouse models [141] and a phase I study is currently recruiting patients
with advanced liver cancer for HCC therapeutic intervention (NCT01829971).
It has been described, both in vivo and in vitro, the efficacy of miRNAs to increase the response to
Sorafenib in HCC. Sorafenib, a potent multikinases inhibitor, represents the ongoing therapy approved
for the management of advanced HCC by hampering tumor cell proliferation and angiogenesis. To date,
there are just few evidence of the prognostic role of aberrant serum miRNAs predicting Sorafenib
response [137,142]. It has been described that miR-221 modulates Sorafenib resistance through
inhibition of caspase-3-mediated apoptosis [137]. Also, miR-21 participates to the acquired resistance
to Sorafenib by suppressing autophagy through the Akt/PTEN pathway. Anti-miR-21 oligonucleotides
tested in animal models significantly reduced tumor size by 51.5%, and combination therapy with
Sorafenib resulted in a further reduction of tumor size by 74.5% [143]. Tang et al. generated an artificial
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long non-coding RNA (AlncRNA), which simultaneously targets and inhibits multiple miRNAs
including miR-21, miR-153, miR-216a, miR-217, miR-494 and miR-10a-5p, which have been shown to
be up-regulated in Sorafenib-resistant cells and participate in the mechanisms underlying Sorafenib
resistance. Ad5-AlncRNA inhibited proliferation and induced apoptosis of Sorafenib-resistant cells
and enhanced the effects of Sorafenib in vitro and in animal models by blocking autophagy [144].
In another study, intra-tumor injection of miRNA-122 packaged in exosomes significantly increased
the antitumor efficacy of Sorafenib on HCC in vivo [145]. Finally, rhamnetin, a flavonoid from sea
buckthorn, acts as a promising sensitizer of Sorafenib and overcomes multidrug resistance in HCC by
regulating miR-34 and NOTCH-1 expression [146]. Relying on the results obtained in vivo and in vitro,
Regulus Therapeutics (San Diego, CA, USA) is developing anti-miR122 (RG-101) and anti-miR103
(RG-125) for anti-HCV and anti-NASH, respectively. Enrollment of patients in phase II has been
completed for anti-miR122 and enrollment of patients in phase I is about to start for anti-miR103 with
AstraZeneca (London, UK) [147].
In summary, the evaluation of potential biomarkers predicting the response to anti-tumoral
treatments is a huge challenge for clinical personalized interventions. Thus, analysis of circulating
miRNAs may be a valuable strategy for the diagnosis of HCC and prediction of survival of patients
receiving Sorafenib treatment.
It is worth discussing whether the reported changes in miRNAs are reversible upon
pharmacological treatments of NASH. For instance, it has been described that miR-21 plays an
important role in NASH pathogenesis by inhibiting PPARα. Rodrigues et al. found that miR-21
ablation in a mouse model of NASH reduced hepatic steatosis, inflammation and fibrosis and these
effects were partly attributable to PPARα. Notably, antagomiR-21 combined with OCA administration,
which activates FXR, inhibited NASH development suggesting that this combination could represent an
interesting therapeutic strategy for the treatment of NASH [122]. Additionally, chenodeoxycholic acid
(CDCA) therapy seems to modulate the expression of the miRNAome in primary human hepatocytes.
Krattinger et al. showed that CDCA influences the expression of distinct miRNAs that regulate the
expression of genes implicated in bile and lipid metabolism. In particular, miR-34a was suppressed by
CDCA and inversely correlated with key genes involved in bile acid homeostasis [148]. Furthermore,
changes in miRNA profile associated with metformin treatment occur in mice fed MCD. In this model
of NASH, the expression of several miRNAs including miR-34a was up-regulated whereas that of
miR-122, miR-101b, miR-194 was decreased upon metformin exposure [149]. These results suggest
that miRNA profile represents a potential tool which may help to clarify the mechanisms underlying
the metformin-mediated improvement of hepatic steatosis and fibrosis.
9. Single Nucleotide Polymorphism Can Modify miRNA Target Sites
SNPs associated with polygenetic disorders, such as NAFLD, can destroy or create miRNA
binding sites. The PNPLA3 isoleucine to methionine substitution at position 148 (rs738409 C>G
encoding for PNPLA3 I148M) is the most robust and well replicated genetic variant associated with
NAFLD pathogenesis and progression [7,150].
It has been speculated that disruption of miRNA target binding by PNPLA3 I148M allele may play
a role and partially explain the effect of this gene variant on fatty liver susceptibility. In silico prediction
analysis revealed that rs738409 G and C alleles show potentially different miRNA binding sites,
suggesting a putative different role in gene regulation. In particular, two miRNAs (hsa-miR-769-3p
and hsa-miR-516a-3p) have been predicted to potentially interact in the 3’UTR region of PNPLA3
gene [151].
In addition, it has been described that PNPLA3 gene lies between two CCCTC-binding
factors-bound sites that could be tested for insulator activity, and an intronic histone 3 lysine 4
trimethylation peak predicts an enhancer element, suggesting an epigenetic modulation of this gene.
Suresh et al. catalogued the SNPs in selected miRNA genes directly or indirectly related to
the Warburg effect through a computational analysis. These SNPs can affect regulation of miRNA
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biogenesis and alter miRNA levels, thereby affecting genes that control aerobic glycolysis, providing
useful information for application in cancer therapy [152].
Finally, it has been described that a putative binding site for miR-491-5p resides in 3’UTR of MMP9,
and the genetic variant (rs1056628 A>C) which is present in this region abrogates its post-transcriptional
regulation affecting gastric cancer susceptibility [153].
10. Concluding Remarks
Genetics, environment and dietetic habits play a key role in NAFLD development and progression.
Epigenetics changes interact with genetic risk factors thus increasing individual susceptibility to
NAFLD and possibly explaining the huge phenotypic variability. To date there are not approved drugs
for NAFLD and liver biopsy remains the gold standard procedure to diagnose its progressive forms.
In this context, there is a growing need to identify novel and trustworthy biomarkers, attempting
to distinguish NASH from simple steatosis and to diagnose fibrosis, thus circulating miRNAs have
become appealing molecule candidates for diagnosis and staging of liver diseases. Moreover, it has
been demonstrated although not in patients that changes in miRNAs are reversible upon treatment
with drugs used as therapies for NASH.
The possibility to assign a specific spectrum of miRNA expression to each stage of NAFLD and to
formulate panels of miRNAs as suitable molecular biomarkers by combining them with the genetic
profile, represents a fundamental innovative breakthrough for identifying new important diagnostic
tools to tailor personalized efficient therapeutic interventions and more accurate prognosis, although
the issue requires further validations.
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Abbreviations
NAFLD Nonalcoholic Fatty Liver Disease
NASH Nonalcoholic Steatohepatitis
HCC Hepatocellular Carcinoma
HBV Viral Hepatitis B
HCV Viral Hepatitis C
T2DM Type 2 Diabetes Mellitus
VAT Visceral Adipose Tissue
ALT Alanine Aminotransferase
AST Aspartate Aminotransferase
BMI Body Mass Index
NAS NAFLD Activity Score
FIB 4 Fibrosis 4
TNM Tumor, Node and Metastasis
SNP Single Nucleotide Polymorphism
PNPLA3 Patatin-like phospholipase domain containing-3
TM6SF2 Transmembrane 6 superfamily member 2
MBOAT7/TMC4 Membrane bound O-acyltransferase domain containing 7-Transmembrane channel-like 4
HFD High Fat Diet
MCD Methionine Choline-deficient Diet
TAA Thioacetamide
VLDL Very Low-Density Lipoprotein
HDL High Density Lipoprotein
DSS Dextran Sulfate Sodium
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CCl4 Carbon Tetrachloride
UDCA Ursodeoxycholic Acid
OCA Obeticholic Acid
FFA Free Fatty Acid
KCs Kupffer cells
CDCA Chenodeoxycholic Acid
HSCs Hepatic Stellate Cells
ATM Adipose Tissue Macrophages
IEC Intestinal Epithelial Cell
ECM Extracellular Matrix
SREBP Sterol Regulatory Element-binding Protein
miRNAs microRNAs
exomiRs Exosomal miRNAs
LPS Lipopolysaccharides
TLRs Toll-like receptors
NF-κB Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells
PPARα Peroxisome Proliferator Activated Receptor-alpha
PPARγ Peroxisome Proliferator Activated Receptor-gamma
PTEN Phosphatase and Tensin Homolog
ACLS-1 Acyl-CoA Synthetase 1 Long-chain Family Member 1
TGF-β/Smad Transforming Growth Factor-Beta/Suppressor of Mothers Against Decapentaplegic
Miscellaneous
AMPK AMP-activated Protein Kinase
AdipoR2 Adiponectin Receptor 2
ATG7 Autophagy-related Gene 7
ATG12-5 Autophagy-related Gene 12-5
AEG-1 Astrocyte Elevated Gene-1
YAP1 Yes-associated Protein
SIRT1 Sirtuin 1
HNF4α Hepatocyte Nuclear Factor 4 Alpha
IL-6 Interleukin 6
IL-8 Interleukin 8
IL-10 Interleukin 10
IL-12p40 p40 Subunit of Interleukin 12
ZO-1 Zonula Occludens-1
UTR Untranslated region
IL-6/STAT3 Interleukin-6/Signal Transducer and Activator of Transcription 3
HNF6 Hepatocyte Nuclear Factor 6
CK-18 Cytokeratin-18
TNF-α Tumor Necrosis Factor-alpha
CCL2 C-C Motif Chemokine Ligand 2 (CCL2)
AGO2 Argonaute-2
HIF1-α Hypoxia-Inducible Factor 1-α
MAPK1 Mitogen-Activated Protein Kinase 1
ABCA1 ATP-binding Cassette Transporter sub-family A member 1
APOA1 Apolipoprotein A1
Col1A1 Type I Collagen A1
αSMA alpha-smooth muscle actin
PI3k/Akt Phosphatidylinositol-3-Kinase/ Protein Kinase B
HMGCR Hydroxymethylglutaryl-CoA Reductase
FGF19 Fibroblast Growth Factor 19
LXRα Liver X Receptor alpha
FXR Farnesoid-X Activated Receptor
iNOS Inducible Nitric oxide synthases
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Gα12 Guanine Nucleotide-binding α-subunit 12
GPCRs G-protein Coupled Receptors
Bcl2 B-cell lymphoma-2
CASP2 Caspase 2
MMP2 Metalloproteinase 2
MMP9 Metalloproteinase 9
HDAC1 Histone deacetylase 1
ERK1 Extracellular Signal-Regulated Kinase 1
SPRY2 Sprouty 2
HBP1 HMG-Box Transcription Factor 1
CCN Central Communication Network
DDIT4 DNA Damage-Inducible Transcript 4
AlncRNA Artificial Long Non-coding RNA
DGCR8 DiGeorge critical region 8
GGT γ Glutamyl Transferase
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